ATE369126T1 - Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung - Google Patents
Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlungInfo
- Publication number
- ATE369126T1 ATE369126T1 AT00939884T AT00939884T ATE369126T1 AT E369126 T1 ATE369126 T1 AT E369126T1 AT 00939884 T AT00939884 T AT 00939884T AT 00939884 T AT00939884 T AT 00939884T AT E369126 T1 ATE369126 T1 AT E369126T1
- Authority
- AT
- Austria
- Prior art keywords
- combination therapy
- weight reduction
- obesity treatment
- phentermine
- weight loss
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13902299P | 1999-06-14 | 1999-06-14 | |
US17856300P | 2000-01-26 | 2000-01-26 | |
US18126500P | 2000-02-09 | 2000-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE369126T1 true ATE369126T1 (de) | 2007-08-15 |
Family
ID=27385274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00939884T ATE369126T1 (de) | 1999-06-14 | 2000-06-14 | Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung |
Country Status (10)
Country | Link |
---|---|
EP (5) | EP2305228B1 (de) |
AT (1) | ATE369126T1 (de) |
AU (1) | AU770068B2 (de) |
CA (2) | CA2686633A1 (de) |
CY (1) | CY1106974T1 (de) |
DE (1) | DE60035870T2 (de) |
DK (1) | DK1187603T3 (de) |
ES (4) | ES2542868T3 (de) |
PT (1) | PT1187603E (de) |
WO (1) | WO2000076493A1 (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7553818B2 (en) | 1999-06-14 | 2009-06-30 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US7674776B2 (en) | 1999-06-14 | 2010-03-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US7056890B2 (en) | 1999-06-14 | 2006-06-06 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US7659256B2 (en) | 1999-06-14 | 2010-02-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US20080103179A1 (en) * | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
WO2002003984A2 (en) * | 2000-07-07 | 2002-01-17 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x |
US6191117B1 (en) * | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
BR0115055A (pt) * | 2000-10-30 | 2003-12-30 | Ortho Mcneil Pharm Inc | Terapia de combinação compreendendo agentes anticonvulsantes e antidiabéticos |
CA2430010A1 (en) * | 2000-11-30 | 2002-06-06 | University Of Florida | Treatments for neurogenetic disorders, impulse control disorders, and wound healing |
EP1496838B1 (de) | 2002-03-12 | 2010-11-03 | Merck Sharp & Dohme Corp. | Substituierte amide |
MXPA04011203A (es) | 2002-05-17 | 2005-07-14 | Univ Duke | Metodo para tratar la obesidad. |
MXPA05006203A (es) * | 2002-12-13 | 2005-08-19 | Cilag Ag | Formulaciones estables de topiramato. |
EP2316456B1 (de) | 2003-04-29 | 2017-06-14 | Orexigen Therapeutics, Inc. | Zubereitungen enthaltend einen Opioidantagonisten und Bupropion zur Beeinflussung von Gewichtsverlust |
CA2553207A1 (en) * | 2004-01-13 | 2005-08-04 | Kishore M. Gadde | Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss |
US7713959B2 (en) | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
JP2008545650A (ja) | 2005-05-20 | 2008-12-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | スルファミド誘導体の製造方法 |
WO2007067341A2 (en) | 2005-11-22 | 2007-06-14 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
US8492431B2 (en) | 2005-12-19 | 2013-07-23 | Janssen Pharmaceutica, N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
TW200812573A (en) | 2006-05-19 | 2008-03-16 | Janssen Pharmaceutica Nv | Co-therapy for the treatment of epilepsy and related disorders |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
US7780730B2 (en) | 2006-09-25 | 2010-08-24 | Iyad Saidi | Nasal implant introduced through a non-surgical injection technique |
KR101479324B1 (ko) * | 2006-11-09 | 2015-01-05 | 오렉시젠 세러퓨틱스 인크. | 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형 |
MX343867B (es) | 2006-11-09 | 2016-11-25 | Orexigen Therapeutics Inc | Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso. |
US8071557B2 (en) | 2007-06-13 | 2011-12-06 | Vivus, Inc. | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors |
AU2014213552B2 (en) * | 2007-06-13 | 2016-11-24 | Vivus, Inc. | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine |
CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
US20090304789A1 (en) | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
US8580298B2 (en) | 2008-06-09 | 2013-11-12 | Vivus, Inc. | Low dose topiramate/phentermine composition and methods of use thereof |
MX2011000090A (es) | 2008-06-23 | 2011-03-02 | Janssen Pharmaceutica Nv | Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]diox in-2-ilmetil)sulfamida. |
US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
US9597220B2 (en) | 2008-11-19 | 2017-03-21 | Spirox, Inc. | Apparatus and methods for correcting nasal valve collapse |
US9248123B2 (en) | 2010-01-11 | 2016-02-02 | Orexigen Therapeutics, Inc. | Methods of providing weight loss therapy in patients with major depression |
WO2013028909A1 (en) * | 2011-08-25 | 2013-02-28 | Sova Pharmaceuticals, Inc. | Combination therapy for the treatment of sleep-related breathing disorders |
AU2013271622B2 (en) | 2012-06-06 | 2018-03-01 | Nalpropion Pharmaceuticals Llc | Methods of treating overweight and obesity |
ES2671997T3 (es) | 2013-02-27 | 2018-06-12 | Spirox, Inc. | Implantes nasales y sistemas |
WO2014134477A1 (en) * | 2013-02-28 | 2014-09-04 | Livelight Llc | Methods and systems for treating overweight individuals |
CN105792670B (zh) | 2013-12-05 | 2021-02-05 | 奇华顿股份有限公司 | 有机化合物 |
US10398545B2 (en) | 2014-08-26 | 2019-09-03 | Spirox, Inc. | Nasal implants and systems and method of use |
KR20180059863A (ko) | 2015-09-25 | 2018-06-05 | 스파이록스 인코포레이티드 | 코 임플란트들 및 시스템들 및 사용 방법 |
US12046341B2 (en) | 2021-10-05 | 2024-07-23 | Bradford Rabin | Methods and systems for electronically adjusting a dosing pattern of a patient undergoing a medical regimen |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
FR2684101B1 (fr) * | 1991-11-22 | 1993-12-31 | Adir Cie | Nouveaux derives de benzoate d'ethanolamine, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
US5384327A (en) | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
US5543405A (en) * | 1993-10-22 | 1996-08-06 | Keown; Wendy J. | Composition and method for weight reduction and long term management of obesity |
US5498629A (en) | 1993-12-23 | 1996-03-12 | Ortho Pharmaceutical Corporation | Anticonvulsant pseudofructopyranose sulfamates |
US5753693A (en) | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder |
US5753694A (en) | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS) |
US5795895A (en) | 1997-06-13 | 1998-08-18 | Anchors; J. Michael | Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug |
UA65607C2 (uk) * | 1998-03-04 | 2004-04-15 | Орто-Макнейл Фармацевтикал, Інк. | Фармацевтична композиція (варіанти) та спосіб її приготування |
-
2000
- 2000-06-14 DE DE60035870T patent/DE60035870T2/de not_active Expired - Lifetime
- 2000-06-14 EP EP20100184981 patent/EP2305228B1/de not_active Expired - Lifetime
- 2000-06-14 EP EP20100184959 patent/EP2308481B1/de not_active Expired - Lifetime
- 2000-06-14 EP EP20100184955 patent/EP2305226B1/de not_active Expired - Lifetime
- 2000-06-14 ES ES10184977.6T patent/ES2542868T3/es not_active Expired - Lifetime
- 2000-06-14 WO PCT/US2000/016434 patent/WO2000076493A1/en active IP Right Grant
- 2000-06-14 CA CA002686633A patent/CA2686633A1/en not_active Abandoned
- 2000-06-14 ES ES00939884T patent/ES2291215T3/es not_active Expired - Lifetime
- 2000-06-14 EP EP00939884A patent/EP1187603B1/de not_active Expired - Lifetime
- 2000-06-14 EP EP20100184977 patent/EP2305227B1/de not_active Expired - Lifetime
- 2000-06-14 AT AT00939884T patent/ATE369126T1/de active
- 2000-06-14 CA CA002377330A patent/CA2377330C/en not_active Expired - Lifetime
- 2000-06-14 ES ES10184955.2T patent/ES2542891T3/es not_active Expired - Lifetime
- 2000-06-14 PT PT00939884T patent/PT1187603E/pt unknown
- 2000-06-14 DK DK00939884T patent/DK1187603T3/da active
- 2000-06-14 AU AU54896/00A patent/AU770068B2/en not_active Expired
- 2000-06-14 ES ES10184959.4T patent/ES2542892T3/es not_active Expired - Lifetime
-
2007
- 2007-11-05 CY CY20071101414T patent/CY1106974T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP2305227A1 (de) | 2011-04-06 |
CA2686633A1 (en) | 2000-12-21 |
ES2542891T3 (es) | 2015-08-12 |
PT1187603E (pt) | 2007-11-16 |
EP2305226B1 (de) | 2015-05-06 |
DE60035870D1 (de) | 2007-09-20 |
DE60035870T2 (de) | 2008-05-08 |
AU770068B2 (en) | 2004-02-12 |
EP2305227B1 (de) | 2015-05-06 |
AU5489600A (en) | 2001-01-02 |
CA2377330A1 (en) | 2000-12-21 |
EP1187603A4 (de) | 2004-02-11 |
ES2542892T3 (es) | 2015-08-12 |
CY1106974T1 (el) | 2012-09-26 |
ES2291215T3 (es) | 2008-03-01 |
EP2305228B1 (de) | 2015-05-06 |
EP1187603A1 (de) | 2002-03-20 |
EP2308481A1 (de) | 2011-04-13 |
DK1187603T3 (da) | 2007-12-17 |
WO2000076493A1 (en) | 2000-12-21 |
EP2308481B1 (de) | 2015-05-06 |
EP2305226A1 (de) | 2011-04-06 |
CA2377330C (en) | 2009-11-24 |
ES2542868T3 (es) | 2015-08-12 |
EP1187603B1 (de) | 2007-08-08 |
EP2305228A1 (de) | 2011-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE369126T1 (de) | Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung | |
HUP0303917A2 (hu) | Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére | |
IL267381A (en) | A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders | |
BR0211062A (pt) | Combinações para o tratamento de distúrbios inflamatórios | |
HUP0301729A2 (hu) | Gyógyszer szívelégtelenség megelżzésére és kezelésére | |
HUP0002755A2 (hu) | Eljárások szklerózis multiplexben szenvedő betegek kezelésére konszenzus interferonnal | |
WO2003030823A3 (en) | Combinations for the treatment of immunoinflammatory disorders | |
EP0824917A3 (de) | Verwendung eines Serotonin 5-HT1F Agonists zur Herstellung eines Wirkstoffs für die Behandlung oder die Verbesserung des Schnupfens oder der allergischen Rhinitis | |
BR9908510A (pt) | Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana | |
HK1081862A1 (en) | Synergistic combination comprising roflumilast and (r,r)-formoterol | |
DE69303305D1 (de) | Mittel zur Behandlung chronischer Ermüdungserscheinungen | |
EP1825851A3 (de) | Kombinationstherapie zur Gewichtsreduzierung und Fettleibigkeitsbehandlung | |
TW200501958A (en) | A therapeutic agent for treating a behavioral disorder | |
DK1156795T3 (da) | Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens | |
DK1235573T3 (da) | Kombination af riluzol og gabapentin og anvendelse deraf som medikament ved behandling af motorneuronsygdomme | |
WO2004100899A3 (en) | Use of secretin in treatments of disorders associated with the amygdala |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1187603 Country of ref document: EP |